IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C

The aim of the study was to observe the frequency of neutropenia during Pegylated Interferon/Ribavirin therapy in patient with chronic hepatitis C; to compare the efficacy of two strategies of management of neutropenia--with Interferon dose modification and with Neupogen administration; to compare t...

Full description

Saved in:
Bibliographic Details
Published in:Georgian medical news 2007-06 (147), p.52
Main Authors: Sharvadze, L, Gochitashvili, N, Tophuria, A, Bolokadze, N, Tsertsvadze, T
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Female
Filgrastim
Granulocyte Colony-Stimulating Factor - therapeutic use
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - epidemiology
Humans
Interferons - adverse effects
Interferons - therapeutic use
Male
Middle Aged
Neutropenia - chemically induced
Neutropenia - drug therapy
Recombinant Proteins
Ribavirin - adverse effects
Ribavirin - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of the study was to observe the frequency of neutropenia during Pegylated Interferon/Ribavirin therapy in patient with chronic hepatitis C; to compare the efficacy of two strategies of management of neutropenia--with Interferon dose modification and with Neupogen administration; to compare the effectiveness rate of sustained viral response (SVR) in patients with Pegylated Interferon dose modification and in patients treated by using granulocyte colony-stimulating factor G-CSF-filgrastim. (Neupogen). Study enrolled 47 patients with chronic active hepatitis C, aged 23-64. (38 male and 9 female). All patients had HCV genotype 1b. Significant neurtopenia (ANC
ISSN:1512-0112